EyePoint Pharmaceuticals, Inc. (EYPT)
Largest Insider Buys in Sector
EYPT Stock Price History Chart
EYPT Stock Performance
About EyePoint Pharmaceuticals, Inc.
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
Insider Activity of EyePoint Pharmaceuticals, Inc.
Over the last 12 months, insiders at EyePoint Pharmaceuticals, Inc. have bought $89.68M and sold $120.66M worth of EyePoint Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at EyePoint Pharmaceuticals, Inc. have bought $29.98M and sold $43.05M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Cormorant Asset Management, LP (10 percent owner) — $1.52B. Zaderej Karen L. (director) — $199,500. ANDO GORAN (director) — $39,750.
The last purchase of 5,000 shares for transaction amount of $39,750 was made by ANDO GORAN (director) on 2024‑08‑21.
List of Insider Buy and Sell Transactions, EyePoint Pharmaceuticals, Inc.
| 2024-08-21 | director | 5,000 0.0082% | $7.95 | $39,750 | -1.10% | |||
| 2024-08-20 | director | 2,567 0.0048% | $7.79 | $19,997 | +16.00% | |||
| 2024-08-19 | director | 12,500 0.0235% | $7.98 | $99,750 | +12.72% | |||
| 2024-08-16 | director | 3,173 0.0057% | $7.88 | $25,003 | 0.00% | |||
| 2024-07-12 | Sale | director | 11,625 0.0274% | $10.06 | $116,995 | 0.00% | ||
| 2024-06-03 | Sale | director | 11,625 0.0233% | $10.30 | $119,705 | -9.11% | ||
| 2024-05-14 | Sale | director | 11,625 0.0227% | $12.65 | $147,045 | -26.95% | ||
| 2024-05-06 | 10 percent owner | 850,000 1.8064% | $11.86 | $10.08M | -18.68% | |||
| 2024-04-18 | 10 percent owner | 581,765 1.2029% | $18.03 | $10.49M | -47.46% | |||
| 2024-02-02 | Sale | SVP & Chief Commercial Officer | 209 0.0007% | $28.49 | $5,954 | -61.15% | ||
| 2024-01-26 | Sale | SVP & Chief Commercial Officer | 26,017 0.0509% | $25.38 | $660,370 | -57.91% | ||
| 2024-01-26 | Sale | Chief Medical Officer | 49,325 0.0975% | $25.66 | $1.27M | -57.91% | ||
| 2024-01-25 | Sale | SVP & Chief Commercial Officer | 600 0.0012% | $25.00 | $15,000 | -54.81% | ||
| 2024-01-25 | Sale | Chief Medical Officer | 600 0.0012% | $25.00 | $15,000 | -54.81% | ||
| 2024-01-24 | Sale | Executive Vice Chair | 29,956 0.0887% | $24.98 | $748,250 | -52.49% | ||
| 2024-01-24 | Sale | SVP & Chief Commercial Officer | 11,300 0.0335% | $25.01 | $282,621 | -52.49% | ||
| 2024-01-24 | Sale | Chief Medical Officer | 11,251 0.0334% | $25.01 | $281,415 | -52.49% | ||
| 2024-01-23 | Sale | Executive Vice Chair | 5,044 0.0144% | $24.97 | $125,950 | -53.90% | ||
| 2024-01-23 | Sale | SVP & Chief Commercial Officer | 900 0.0026% | $25.00 | $22,500 | -53.90% | ||
| 2024-01-23 | Sale | Chief Medical Officer | 5,135 0.0146% | $25.00 | $128,375 | -53.90% |
Insider Historical Profitability
| Cormorant Asset Management, LP | 10 percent owner | 8325000 12.1976% | $8.85 | 6 | 0 | |
| Ocumension Therapeutics | director | 100221 0.1468% | $8.85 | 0 | 3 | |
| Liu Ye | director | 100221 0.1468% | $8.85 | 0 | 4 | |
| Lurker Nancy | director | 97635 0.1431% | $8.85 | 4 | 4 | <0.0001% |
| Jones David Scott | SVP & Chief Commercial Officer | 37962 0.0556% | $8.85 | 0 | 6 | |
| Paggiarino Dario A. | Chief Medical Officer | 36505 0.0535% | $8.85 | 0 | 7 | |
| Zaderej Karen L. | director | 16500 0.0242% | $8.85 | 1 | 0 | |
| ANDO GORAN | director | 13150 0.0193% | $8.85 | 1 | 0 | |
| DICICCO WENDY F | director | 9967 0.0146% | $8.85 | 1 | 0 | |
| Pine Michael Craig | Chief Corp Dev.&Strat. Officer | 4343 0.0064% | $8.85 | 1 | 1 | <0.0001% |
| GUYER DAVID R | director | 1850 0.0027% | $8.85 | 0 | 3 | |
| EW Healthcare Partners, L.P. | 10 percent owner | 3490921 5.1148% | $8.85 | 2 | 9 | +60.73% |
| Ashton Paul | President & CEO | 440741 0.6458% | $8.85 | 0 | 12 | |
| Freedman Lori | VP Corp. Affairs, GC and Sec | 96423 0.1413% | $8.85 | 0 | 5 | |
| Elston George | Chief Financial Officer | 40000 0.0586% | $8.85 | 4 | 0 | +18.73% |
| Landis John B. | director | 40000 0.0586% | $8.85 | 1 | 0 | <0.0001% |
| Godshall Douglas Evan | director | 29500 0.0432% | $8.85 | 1 | 0 | <0.0001% |
| Duker Jay S. | director | 17500 0.0256% | $8.85 | 1 | 0 | <0.0001% |
| Hopper Paul | director | 10000 0.0147% | $8.85 | 1 | 0 | +38.89% |
| Ross Leonard S | Vice President, Finance | 0 0% | $8.85 | 0 | 4 |
Institutional Investor Ownership
| Cormorant Asset Management Lp | $142.48M | 13.24 | 6.89M | +14.16% | +$17.67M | 6.64 | |
| Adage Capital Partners Gp L L C | $98.31M | 9.13 | 4.76M | +6.49% | +$5.99M | 0.18 | |
| Suvretta Capital Management, LLC | $77.8M | 7.23 | 3.76M | -7.22% | -$6.06M | 3.29 | |
| Franklin Templeton Investments | $70.06M | 6.51 | 3.39M | -26.97% | -$25.87M | 0.02 | |
| BlackRock | $57.61M | 5.35 | 2.79M | +28.49% | +$12.78M | <0.01 | |
| T. Rowe Price | $50.97M | 4.73 | 2.47M | -2.25% | -$1.18M | 0.01 | |
| The Vanguard Group | $49.53M | 4.6 | 2.4M | +17.8% | +$7.49M | <0.01 | |
| Millennium Management LLC | $42.3M | 3.93 | 2.05M | +81.32% | +$18.97M | 0.03 | |
| T Rowe Price Investment Management Inc | $33.17M | 3.08 | 1.6M | +2.96% | +$952,654.72 | 0.02 | |
| Essex Woodlands Management Inc | $32.07M | 2.98 | 1.55M | -33.63% | -$16.25M | 9.32 | |
| Citadel Advisors LLC | $28.43M | 2.64 | 1.38M | +12.08% | +$3.06M | 0.02 | |
| Morgan Stanley | $27.74M | 2.58 | 1.34M | +1.76% | +$479,916.09 | <0.01 | |
| Octagon Capital Advisors LP | $22.6M | 2.1 | 1.09M | New | +$22.6M | 0.12 | |
| State Street | $21.34M | 1.98 | 1.03M | +87.53% | +$9.96M | <0.01 | |
| RA Capital Management, L.P. | $19.4M | 1.8 | 938,591 | New | +$19.4M | 0.02 | |
| Goldman Sachs | $17.35M | 1.61 | 839,478 | +47.8% | +$5.61M | <0.01 | |
| Deutsche Bank | $17.27M | 1.61 | 835,722 | +8.46% | +$1.35M | 0.01 | |
| Geode Capital Management | $17.21M | 1.6 | 832,637 | +22.01% | +$3.11M | <0.01 | |
| Ameriprise Financial | $13.92M | 1.29 | 673,348 | -56.17% | -$17.83M | <0.01 | |
| Fiera Capital | $13.87M | 1.29 | 671,118 | New | +$13.87M | 0.04 | |
| FINEPOINT CAPITAL LP | $13.57M | 1.26 | 656,600 | New | +$13.57M | 2.18 | |
| Federated Hermes | $13.29M | 1.24 | 643,176 | -4.69% | -$654,164.16 | 0.03 | |
| Laurion Capital Management LP | $13.01M | 1.21 | 629,396 | -0.63% | -$82,948.71 | 0.09 | |
| Perceptive Advisors | $12.19M | 1.13 | 589,646 | 0% | +$0 | 0.01 | |
| Deerfield Management | $11.98M | 1.11 | 579,594 | New | +$11.98M | 0.03 | |
| Woodline Partners LP | $9.92M | 0.92 | 479,682 | +19.92% | +$1.65M | 0.09 | |
| Oracle Investment Management Inc | $9.55M | 0.89 | 461,857 | +15.02% | +$1.25M | 1.29 | |
| UBS | $9.44M | 0.88 | 456,626 | -20.47% | -$2.43M | <0.01 | |
| Marshall Wace | $8.04M | 0.75 | 388,955 | New | +$8.04M | 0.01 | |
| Candriam S C A | $7.92M | 0.74 | 383,000 | +173.57% | +$5.02M | 0.05 | |
| Northern Trust | $6.66M | 0.62 | 322,225 | +34.47% | +$1.71M | <0.01 | |
| Schroder Investment Management Group | $6.33M | 0.59 | 306,206 | +70.11% | +$2.61M | 0.01 | |
| SEB | $5.85M | 0.54 | 282,814 | New | +$5.85M | 0.03 | |
| AXA | $5.44M | 0.51 | 263,335 | -8.29% | -$492,111.32 | 0.02 | |
| Invesco | $5.22M | 0.49 | 252,593 | -12.4% | -$739,159.30 | <0.01 | |
| Vr Adviser Llc | $5.17M | 0.48 | 250,000 | 0% | +$0 | 0.25 | |
| Silverarc Capital Management Llc | $5.13M | 0.48 | 247,968 | New | +$5.13M | 0.05 | |
| Lord Abbett | $5.01M | 0.47 | 242,580 | -34.61% | -$2.65M | 0.02 | |
| Jane Street Capital | $4.44M | 0.41 | 214,694 | +207.17% | +$2.99M | <0.01 | |
| New York State Common Retirement Fund | $4.11M | 0.38 | 198,760 | +823.99% | +$3.66M | 0.01 | |
| Walleye Capital | $3.86M | 0.36 | 186,958 | New | +$3.86M | 0.01 | |
| Bank of America | $3.63M | 0.34 | 175,404 | +123.6% | +$2M | <0.0001 | |
| PFM Health Sciences | $3.53M | 0.33 | 170,871 | 0% | +$0 | 0.1 | |
| Barclays | $3.42M | 0.32 | 165,687 | +3.79% | +$124,959.26 | <0.01 | |
| Connor Clark & Lunn Investment Management Ltd | $3.41M | 0.32 | 165,112 | +33.41% | +$854,663.15 | 0.01 | |
| Nuveen | $3.24M | 0.3 | 156,573 | +26.74% | +$682,750.79 | <0.01 | |
| BNY Mellon | $3.19M | 0.3 | 154,504 | +19.21% | +$514,557.90 | <0.01 | |
| ESSEX INVESTMENT MANAGEMENT CO LLC | $3.1M | 0.29 | 149,819 | +1.54% | +$47,086.26 | 0.62 | |
| Alyeska Investment Group L P | $3.06M | 0.28 | 147,837 | -20.88% | -$806,192.06 | 0.02 | |
| Prudential Financial | $3.04M | 0.28 | 147,265 | +21.61% | +$540,933.98 | <0.01 |